Stay updated on Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Sign up to get notified when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.

Latest updates to the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page
- CheckyesterdayChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.5%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe modernization of the ClinicalTrials.gov data ingest has been postponed from June 2025 to July 2025, and the revision version has been updated from v2.16.3 to v2.16.4.SummaryDifference0.5%
- Check22 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check30 days agoChange DetectedThe page has been updated to reflect a new version (v2.16.2) and has removed a previous citation regarding the International Myeloma Working Group's response criteria.SummaryDifference0.2%
- Check37 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check44 days agoChange DetectedThe page has been updated to include new references related to multiple myeloma studies, while previous references have been removed. Additionally, the version number has been updated from v2.15.2 to v2.16.0.SummaryDifference5%
Stay in the know with updates to Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.